{
  "content": "Propranolol Betaxolol Atenolol Verapamil Diltiazem Bevantolol Bisoprolol Digoxin Carvedilol 0 500 1000 1500 Cost-effectiveness (not costs per QALY, $US/QALY) Fig. 2. Cost-effectiveness (bars) of rate-control drugs in patients with newly diagnosed atrial fibrillation between January 1, 2013 and Decem-ber 31, 2015 in Korea. All drugs remained cost-effective at a willingness-to-pay threshold of $30000 per quality-adjusted life year (QALY).\nFig. 3. Cost-effectiveness (bars) of rhythm-control drugs in patients with newly diagnosed atrial fibrillation between January 1, 2013 and Decem-ber 31, 2015 in Korea. All drugs remained cost-effective at a willingness-to-pay threshold of $30000 per quality-adjusted life years (QALY).",
  "source": "https://pdfs.semanticscholar.org/798d/e6aa4ebeb8836fdffb27a98ab4195330069c.pdf",
  "chunk_id": "77f0ca25-be47-4bba-bb39-5c83e694b401",
  "similarity_score": 0.31865644454956055,
  "query": "cost effectiveness economic analysis amiodarone beta-blockers atrial fibrillation healthcare costs hospitalization reduction",
  "rank": 10,
  "title": "Cost-effectiveness of rate- and rhythm-control drugs for treating atrial fibrillation in Korea",
  "authors": "Min Kim, Woojin Kim, Changsoo Kim, Boyoung Joung",
  "year": "2019",
  "journal": "Yonsei Medical Journal",
  "reference": "Kim, M., Kim, W., Kim, C., & Joung, B. (2019). Cost-effectiveness of rate- and rhythm-control drugs for treating atrial fibrillation in Korea. Yonsei Medical Journal, 60(12), 1157-1163. https://doi.org/10.3349/ymj.2019.60.12.1157",
  "doi": "10.3349/ymj.2019.60.12.1157",
  "chunk_index": 41,
  "total_chunks": 62,
  "retrieved_at": "2025-07-24T21:58:16.915741"
}